Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

LRP1 and APOA1 Polymorphisms: Impact on Warfarin International Normalized Ratio-Related Phenotypes.

Journal of cardiovascular pharmacology - 1 Jul 2020

Li Dan, Luo Zhi-Ying, Chen Yi, Zhu Hong, Song Guo-Bao, Zhou Xin-Ming, Yan Han, Zhou Hong-Hao, Zhang Wei, Li Xi

Abstract excerpt

Warfarin international normalized ratio (INR)-related phenotypes such as the percentage of INR time in the therapeutic range (PTTR) and INR variability are associated with warfarin adverse reactions. However, INR-related phenotypes greatly vary among patients, and the underlying mechanism remains unclear. As a key cofactor for coagulation proteins, vitamin K can affect warfarin INR values. The aim of this study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Apolipoprotein A-I

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood Coagulation

Share to Drug Monitoring

Share to International Normalized Ratio

Share to Low Density Lipoprotein Receptor-Related Protein-1

Share to Pharmacogenomic Variants

Share to Warfarin

Source

Identifiers

PMID: 32282500
DOI: 10.1097/FJC.0000000000000834

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

LRP1 and APOA1 Polymorphisms: Impact on Warfarin International Normalized Ratio-Related Phenotypes.PMID 32282500Read ↗

Integrated analysis of clinical and genetic factors on the interindividual variation of warfarin anticoagulation efficacy in clinical practice.Semantic proximity Read ↗

Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case SeriesSemantic proximity Read ↗

Gene polymorphisms and the risk of warfarin-induced bleeding complications at therapeutic international normalized ratio (INR).Semantic proximity Read ↗

Pharmacogenetics of Novel Oral Anticoagulants: A Review of Identified Gene Variants & Future PerspectivesSemantic proximity Read ↗

An ADR pharmaceutical care for severe gastrointestinal bleeding of rivaroxaban in a patient with non-valvular atrial fibrillation based on TDM and genetic testingSemantic proximity Read ↗

LRP1 polymorphisms associated with warfarin stable dose in Chinese patients: a stepwise conditional analysis.Semantic proximity Read ↗

Interindividual Variability of Apixaban Plasma Concentrations: Influence of Clinical and Genetic Factors in a Real-Life Cohort of Atrial Fibrillation Patients.Semantic proximity Read ↗

Bleeding Events Associated with Rivaroxaban Therapy in Naive Patients with Nonvalvular Atrial Fibrillation: A Longitudinal Study from a Genetic Perspective with INR Follow-Up.Semantic proximity Read ↗

Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.Semantic proximity Read ↗

Effect of Gene Polymorphism on the Pharmacokinetics and Clinical Outcomes of Rivaroxaban: State-of-the-Art ReviewSemantic proximity Read ↗

International warfarin genotype-guided dosing algorithms in the Turkish population and their preventive effects on major and life-threatening hemorrhagic events.Semantic proximity Read ↗

Mutant CYP3A4/5 Correlated with Clinical Outcomes by Affecting Rivaroxaban Pharmacokinetics and Pharmacodynamics in Patients with Atrial Fibrillation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.